通过人工抗原呈递细胞筛选HLA - A2限制性CML28肽段

Selection of HLA-A2 restricted CML28 peptide by artificial antigen-presenting cells.

作者信息

Mao Hanwen, Geng Zhe, Liu Wenli, Sun Hanying, Huang Wei

机构信息

Department of Hematology, Tongji Hospital, Tongji Medical College, Hua Zhong University of Science and Technology, Wu Han, Hubei, China.

出版信息

J Immunother. 2008 Jun;31(5):487-90. doi: 10.1097/CJI.0b013e318176facc.

DOI:10.1097/CJI.0b013e318176facc

PMID:18463536

Abstract

Chronic myelogenous leukemia (CML) 28 is a broadly immunogenic antigen that can have an antileukemia effect. We adopted the SYFPEITHI database to predict human leukocyte antigen-A2 restricted CML28 peptide. We designed artificial antigen-presenting cells (aAPCs) by coating micro beads with human leukocyte antigen-A2-immunoglobulin dimer and CD28-specific antibody. We used the selected peptides-pulsed aAPCs to induce cytotoxic T lymphocytes (CTLs), to choose the CML28 peptide, which was best for inducing CTLs. The result showed that the peptides-pulsed aAPCs could induce CTLs and that the peptide VLTFALDSV was the best choice for significantly inducing specific CTLs.

摘要

慢性粒细胞白血病（CML）28是一种具有广泛免疫原性的抗原，可产生抗白血病作用。我们采用SYFPEITHI数据库预测人类白细胞抗原-A2限制性CML28肽。我们通过用人白细胞抗原-A2-免疫球蛋白二聚体和CD28特异性抗体包被微珠来设计人工抗原呈递细胞（aAPC）。我们使用选定的肽脉冲aAPC来诱导细胞毒性T淋巴细胞（CTL），以选择最适合诱导CTL的CML28肽。结果表明，肽脉冲aAPC可诱导CTL，且肽VLTFALDSV是显著诱导特异性CTL的最佳选择。